Loading…
Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area
Hepatitis B virus reactivation (HBVr) is not uncommon in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Hepatitis B surface antigen (HBsAg)-positive patients receiving allo-HSCT have a very high risk of HBVr. However, the validity of prophylactic antiviral treatment in HB...
Saved in:
| Published in: | Annals of hematology 2022-03, Vol.101 (3), p.631-641 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c2906-6bdfd0a17cbbe374c4b6b3d75cbea417888089d75c1ce6df6be6de2cd1a87edd3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c2906-6bdfd0a17cbbe374c4b6b3d75cbea417888089d75c1ce6df6be6de2cd1a87edd3 |
| container_end_page | 641 |
| container_issue | 3 |
| container_start_page | 631 |
| container_title | Annals of hematology |
| container_volume | 101 |
| creator | Wu, Yibo Chen, Yi Zhu, Panpan Ye, Baodong Lu, Ying Shi, Jimin Tan, Yamin Zhao, Yanmin Yu, Jian Lai, Xiaoyu Lan, Jianping Si, Ting Ni, Lihong Huang, He Luo, Yi |
| description | Hepatitis B virus reactivation (HBVr) is not uncommon in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Hepatitis B surface antigen (HBsAg)-positive patients receiving allo-HSCT have a very high risk of HBVr. However, the validity of prophylactic antiviral treatment in HBsAg-positive allo-HSCT recipients has not been well studied. We aimed to add experience in dealing with HBsAg-positive patients following allo-HSCT. We conducted a cohort study that included 11 years of data of HBsAg-positive allo-HSCT patients in multiple centers. The cumulative incidence of HBVr with antiviral prophylaxis at 60 months following transplantation was 8.9%. Both lamivudine (LAM) and entecavir (ETV) effectively reduced the incidence of HBVr. Patients with absent-mild cGVHD had a lower HBVr rate than that of patients with moderate-severe cGVHD (HR = 0.201,
P
= 0.020). The incidence of HBsAg seroclearance at 60 months following transplantation was 34.3%. Recipients accepting from anti-HBs–negative donors were associated with a lower HBsAg seroclearance rate than that of those accepting from anti-HBs–positive donors (HR=0.255,
P |
| doi_str_mv | 10.1007/s00277-021-04730-6 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2616610673</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2616610673</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2906-6bdfd0a17cbbe374c4b6b3d75cbea417888089d75c1ce6df6be6de2cd1a87edd3</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQtRCILoU_wAFZ4sLFYDtZO-FWqkKRKnEBrpHjTHZdJXawncL-XX4J490CEgd88MfMm_ee7SHkueCvBef6TeJcas24FIzXuuJMPSAbUVeS8W1TPyQb3lYt2-I4I09SuuVcyKaWj8lZVbeNQOSG_LwaR7DZ3YGHlGgY6RLDsj9MBoOWGo8pF81E8x6iWQ7UeRphWK3zO3r97iseCvLOZBc8HUPEYLrYsSUkV1gxb93iwOeE2WkK30uhwc0OFVFhD7PJYQkOil7KMFMLE-pF49MyoYEj9Vtq6LxO2THnU3Z5LUG0BT8WiEhvgY4xzGj46Ar8AHPxj_aekkejmRI8u1_PyZf3V58vr9nNpw8fLy9umJUtV0z1wzhwI7Tte6h0bete9dWgt7YHUwvdNA1v2nIWFtQwqh5nkHYQptEwDNU5eXXixRf8tkLK3exSuYvxENbUSSWUElzpCqEv_4HehjXifQpK1g1HpRZR8oSyMaQUYeyW6GYTD53gXemA7tQBHXZAd-yATmHRi3vqtZ9h-FPy-8sRUJ0ACVN-B_Gv9n9ofwFiMsOi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2624800899</pqid></control><display><type>article</type><title>Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area</title><source>Springer Nature</source><creator>Wu, Yibo ; Chen, Yi ; Zhu, Panpan ; Ye, Baodong ; Lu, Ying ; Shi, Jimin ; Tan, Yamin ; Zhao, Yanmin ; Yu, Jian ; Lai, Xiaoyu ; Lan, Jianping ; Si, Ting ; Ni, Lihong ; Huang, He ; Luo, Yi</creator><creatorcontrib>Wu, Yibo ; Chen, Yi ; Zhu, Panpan ; Ye, Baodong ; Lu, Ying ; Shi, Jimin ; Tan, Yamin ; Zhao, Yanmin ; Yu, Jian ; Lai, Xiaoyu ; Lan, Jianping ; Si, Ting ; Ni, Lihong ; Huang, He ; Luo, Yi</creatorcontrib><description>Hepatitis B virus reactivation (HBVr) is not uncommon in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Hepatitis B surface antigen (HBsAg)-positive patients receiving allo-HSCT have a very high risk of HBVr. However, the validity of prophylactic antiviral treatment in HBsAg-positive allo-HSCT recipients has not been well studied. We aimed to add experience in dealing with HBsAg-positive patients following allo-HSCT. We conducted a cohort study that included 11 years of data of HBsAg-positive allo-HSCT patients in multiple centers. The cumulative incidence of HBVr with antiviral prophylaxis at 60 months following transplantation was 8.9%. Both lamivudine (LAM) and entecavir (ETV) effectively reduced the incidence of HBVr. Patients with absent-mild cGVHD had a lower HBVr rate than that of patients with moderate-severe cGVHD (HR = 0.201,
P
= 0.020). The incidence of HBsAg seroclearance at 60 months following transplantation was 34.3%. Recipients accepting from anti-HBs–negative donors were associated with a lower HBsAg seroclearance rate than that of those accepting from anti-HBs–positive donors (HR=0.255,
P
< 0.001). The peripheral blood stem cell (PBSC) donor source had a higher HBsAg seroclearance rates than that of the PBSC plus bone marrow stem cell source (HR = 4.700,
P
= 0.047). The prophylactic antiviral treatment effectively reduced HBVr in HBsAg-positive recipients receiving allo-HSCT. HBsAg-positive recipients accept anti-HBs-positive PBSC donor sources may facilitate the acquisition of HBsAg seroclearance after transplantation.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-021-04730-6</identifier><identifier>PMID: 34981143</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Antigens ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Bone marrow ; Cytomegalovirus ; Disease prevention ; Female ; Graft versus host disease ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hepatitis B ; Hepatitis B - blood ; Hepatitis B - etiology ; Hepatitis B - prevention & control ; Hepatitis B - virology ; Hepatitis B Surface Antigens - blood ; Hepatitis B virus - drug effects ; Hepatitis B virus - physiology ; Hospitals ; Humans ; Laboratories ; Lamivudine - therapeutic use ; Leukemia ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Retrospective Studies ; Serology ; Stem cell transplantation ; Transplantation, Homologous - adverse effects ; Virus Activation - drug effects ; Young Adult</subject><ispartof>Annals of hematology, 2022-03, Vol.101 (3), p.631-641</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2906-6bdfd0a17cbbe374c4b6b3d75cbea417888089d75c1ce6df6be6de2cd1a87edd3</citedby><cites>FETCH-LOGICAL-c2906-6bdfd0a17cbbe374c4b6b3d75cbea417888089d75c1ce6df6be6de2cd1a87edd3</cites><orcidid>0000-0001-7051-219X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34981143$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Yibo</creatorcontrib><creatorcontrib>Chen, Yi</creatorcontrib><creatorcontrib>Zhu, Panpan</creatorcontrib><creatorcontrib>Ye, Baodong</creatorcontrib><creatorcontrib>Lu, Ying</creatorcontrib><creatorcontrib>Shi, Jimin</creatorcontrib><creatorcontrib>Tan, Yamin</creatorcontrib><creatorcontrib>Zhao, Yanmin</creatorcontrib><creatorcontrib>Yu, Jian</creatorcontrib><creatorcontrib>Lai, Xiaoyu</creatorcontrib><creatorcontrib>Lan, Jianping</creatorcontrib><creatorcontrib>Si, Ting</creatorcontrib><creatorcontrib>Ni, Lihong</creatorcontrib><creatorcontrib>Huang, He</creatorcontrib><creatorcontrib>Luo, Yi</creatorcontrib><title>Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Hepatitis B virus reactivation (HBVr) is not uncommon in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Hepatitis B surface antigen (HBsAg)-positive patients receiving allo-HSCT have a very high risk of HBVr. However, the validity of prophylactic antiviral treatment in HBsAg-positive allo-HSCT recipients has not been well studied. We aimed to add experience in dealing with HBsAg-positive patients following allo-HSCT. We conducted a cohort study that included 11 years of data of HBsAg-positive allo-HSCT patients in multiple centers. The cumulative incidence of HBVr with antiviral prophylaxis at 60 months following transplantation was 8.9%. Both lamivudine (LAM) and entecavir (ETV) effectively reduced the incidence of HBVr. Patients with absent-mild cGVHD had a lower HBVr rate than that of patients with moderate-severe cGVHD (HR = 0.201,
P
= 0.020). The incidence of HBsAg seroclearance at 60 months following transplantation was 34.3%. Recipients accepting from anti-HBs–negative donors were associated with a lower HBsAg seroclearance rate than that of those accepting from anti-HBs–positive donors (HR=0.255,
P
< 0.001). The peripheral blood stem cell (PBSC) donor source had a higher HBsAg seroclearance rates than that of the PBSC plus bone marrow stem cell source (HR = 4.700,
P
= 0.047). The prophylactic antiviral treatment effectively reduced HBVr in HBsAg-positive recipients receiving allo-HSCT. HBsAg-positive recipients accept anti-HBs-positive PBSC donor sources may facilitate the acquisition of HBsAg seroclearance after transplantation.</description><subject>Adult</subject><subject>Antigens</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Bone marrow</subject><subject>Cytomegalovirus</subject><subject>Disease prevention</subject><subject>Female</subject><subject>Graft versus host disease</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - therapeutic use</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hepatitis B</subject><subject>Hepatitis B - blood</subject><subject>Hepatitis B - etiology</subject><subject>Hepatitis B - prevention & control</subject><subject>Hepatitis B - virology</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B virus - physiology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Lamivudine - therapeutic use</subject><subject>Leukemia</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Retrospective Studies</subject><subject>Serology</subject><subject>Stem cell transplantation</subject><subject>Transplantation, Homologous - adverse effects</subject><subject>Virus Activation - drug effects</subject><subject>Young Adult</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9Uk1v1DAQtRCILoU_wAFZ4sLFYDtZO-FWqkKRKnEBrpHjTHZdJXawncL-XX4J490CEgd88MfMm_ee7SHkueCvBef6TeJcas24FIzXuuJMPSAbUVeS8W1TPyQb3lYt2-I4I09SuuVcyKaWj8lZVbeNQOSG_LwaR7DZ3YGHlGgY6RLDsj9MBoOWGo8pF81E8x6iWQ7UeRphWK3zO3r97iseCvLOZBc8HUPEYLrYsSUkV1gxb93iwOeE2WkK30uhwc0OFVFhD7PJYQkOil7KMFMLE-pF49MyoYEj9Vtq6LxO2THnU3Z5LUG0BT8WiEhvgY4xzGj46Ar8AHPxj_aekkejmRI8u1_PyZf3V58vr9nNpw8fLy9umJUtV0z1wzhwI7Tte6h0bete9dWgt7YHUwvdNA1v2nIWFtQwqh5nkHYQptEwDNU5eXXixRf8tkLK3exSuYvxENbUSSWUElzpCqEv_4HehjXifQpK1g1HpRZR8oSyMaQUYeyW6GYTD53gXemA7tQBHXZAd-yATmHRi3vqtZ9h-FPy-8sRUJ0ACVN-B_Gv9n9ofwFiMsOi</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Wu, Yibo</creator><creator>Chen, Yi</creator><creator>Zhu, Panpan</creator><creator>Ye, Baodong</creator><creator>Lu, Ying</creator><creator>Shi, Jimin</creator><creator>Tan, Yamin</creator><creator>Zhao, Yanmin</creator><creator>Yu, Jian</creator><creator>Lai, Xiaoyu</creator><creator>Lan, Jianping</creator><creator>Si, Ting</creator><creator>Ni, Lihong</creator><creator>Huang, He</creator><creator>Luo, Yi</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7051-219X</orcidid></search><sort><creationdate>20220301</creationdate><title>Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area</title><author>Wu, Yibo ; Chen, Yi ; Zhu, Panpan ; Ye, Baodong ; Lu, Ying ; Shi, Jimin ; Tan, Yamin ; Zhao, Yanmin ; Yu, Jian ; Lai, Xiaoyu ; Lan, Jianping ; Si, Ting ; Ni, Lihong ; Huang, He ; Luo, Yi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2906-6bdfd0a17cbbe374c4b6b3d75cbea417888089d75c1ce6df6be6de2cd1a87edd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Antigens</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Bone marrow</topic><topic>Cytomegalovirus</topic><topic>Disease prevention</topic><topic>Female</topic><topic>Graft versus host disease</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - therapeutic use</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hepatitis B</topic><topic>Hepatitis B - blood</topic><topic>Hepatitis B - etiology</topic><topic>Hepatitis B - prevention & control</topic><topic>Hepatitis B - virology</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B virus - physiology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Lamivudine - therapeutic use</topic><topic>Leukemia</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Retrospective Studies</topic><topic>Serology</topic><topic>Stem cell transplantation</topic><topic>Transplantation, Homologous - adverse effects</topic><topic>Virus Activation - drug effects</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Yibo</creatorcontrib><creatorcontrib>Chen, Yi</creatorcontrib><creatorcontrib>Zhu, Panpan</creatorcontrib><creatorcontrib>Ye, Baodong</creatorcontrib><creatorcontrib>Lu, Ying</creatorcontrib><creatorcontrib>Shi, Jimin</creatorcontrib><creatorcontrib>Tan, Yamin</creatorcontrib><creatorcontrib>Zhao, Yanmin</creatorcontrib><creatorcontrib>Yu, Jian</creatorcontrib><creatorcontrib>Lai, Xiaoyu</creatorcontrib><creatorcontrib>Lan, Jianping</creatorcontrib><creatorcontrib>Si, Ting</creatorcontrib><creatorcontrib>Ni, Lihong</creatorcontrib><creatorcontrib>Huang, He</creatorcontrib><creatorcontrib>Luo, Yi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Yibo</au><au>Chen, Yi</au><au>Zhu, Panpan</au><au>Ye, Baodong</au><au>Lu, Ying</au><au>Shi, Jimin</au><au>Tan, Yamin</au><au>Zhao, Yanmin</au><au>Yu, Jian</au><au>Lai, Xiaoyu</au><au>Lan, Jianping</au><au>Si, Ting</au><au>Ni, Lihong</au><au>Huang, He</au><au>Luo, Yi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>101</volume><issue>3</issue><spage>631</spage><epage>641</epage><pages>631-641</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Hepatitis B virus reactivation (HBVr) is not uncommon in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Hepatitis B surface antigen (HBsAg)-positive patients receiving allo-HSCT have a very high risk of HBVr. However, the validity of prophylactic antiviral treatment in HBsAg-positive allo-HSCT recipients has not been well studied. We aimed to add experience in dealing with HBsAg-positive patients following allo-HSCT. We conducted a cohort study that included 11 years of data of HBsAg-positive allo-HSCT patients in multiple centers. The cumulative incidence of HBVr with antiviral prophylaxis at 60 months following transplantation was 8.9%. Both lamivudine (LAM) and entecavir (ETV) effectively reduced the incidence of HBVr. Patients with absent-mild cGVHD had a lower HBVr rate than that of patients with moderate-severe cGVHD (HR = 0.201,
P
= 0.020). The incidence of HBsAg seroclearance at 60 months following transplantation was 34.3%. Recipients accepting from anti-HBs–negative donors were associated with a lower HBsAg seroclearance rate than that of those accepting from anti-HBs–positive donors (HR=0.255,
P
< 0.001). The peripheral blood stem cell (PBSC) donor source had a higher HBsAg seroclearance rates than that of the PBSC plus bone marrow stem cell source (HR = 4.700,
P
= 0.047). The prophylactic antiviral treatment effectively reduced HBVr in HBsAg-positive recipients receiving allo-HSCT. HBsAg-positive recipients accept anti-HBs-positive PBSC donor sources may facilitate the acquisition of HBsAg seroclearance after transplantation.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34981143</pmid><doi>10.1007/s00277-021-04730-6</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7051-219X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2022-03, Vol.101 (3), p.631-641 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2616610673 |
| source | Springer Nature |
| subjects | Adult Antigens Antiviral Agents - therapeutic use Antiviral drugs Bone marrow Cytomegalovirus Disease prevention Female Graft versus host disease Guanine - analogs & derivatives Guanine - therapeutic use Hematology Hematopoietic Stem Cell Transplantation - adverse effects Hepatitis B Hepatitis B - blood Hepatitis B - etiology Hepatitis B - prevention & control Hepatitis B - virology Hepatitis B Surface Antigens - blood Hepatitis B virus - drug effects Hepatitis B virus - physiology Hospitals Humans Laboratories Lamivudine - therapeutic use Leukemia Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Retrospective Studies Serology Stem cell transplantation Transplantation, Homologous - adverse effects Virus Activation - drug effects Young Adult |
| title | Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T02%3A39%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20prophylactic%20antiviral%20therapy%20in%20reducing%20HBV%20reactivation%20for%20HBsAg-positive%20recipients%20following%20allogeneic%20hematopoietic%20stem%20cell%20transplantation:%20a%20multi-institutional%20experience%20from%20an%20HBV%20endemic%20area&rft.jtitle=Annals%20of%20hematology&rft.au=Wu,%20Yibo&rft.date=2022-03-01&rft.volume=101&rft.issue=3&rft.spage=631&rft.epage=641&rft.pages=631-641&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-021-04730-6&rft_dat=%3Cproquest_cross%3E2616610673%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2906-6bdfd0a17cbbe374c4b6b3d75cbea417888089d75c1ce6df6be6de2cd1a87edd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2624800899&rft_id=info:pmid/34981143&rfr_iscdi=true |